Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4451 | daily syndromic surveillance Wiki | 1.00 |
| drug4588 | monthly serologic IgM/G test Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study aims to quantify and follow the cumulative incidence of SARS-CoV-2 infection in the French population using serological tests and to assess the determinants of infection from Constances, E3N-E4N, ELFE-Epipage 2 and NutriNet-Santé cohorts.
Description: Simple and corrected estimate of the number of seropositive individuals/number of individuals at risk in different strata, based on weighting and calibration and taking into account the random cohort effect.
Measure: Cumulative incidence of SARS-Cov2 infection in the general population. Time: 8 monthsDescription: Decay kinetics estimated by mixed effect model with repeated data per subject
Measure: Maintenance over time of the acquisition of anti-SARS-Cov2 antibodies Time: 8 monthsDescription: Rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infection during a time frame of 8 months
Measure: Rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infection Time: 8 monthsDescription: Proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social déterminants during a time frame of 8 months.
Measure: Proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social determinants Time: 8 monthsDescription: Proportion of tests proposed, accepted, performed, based on social and demographic characteristics during a time frame of 8 months.
Measure: Proportion of tests proposed, accepted, performed, based on social and demographic characteristics Time: 8 monthsDescription: Proportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings / reasons, duration, frequency) and association with the level of seroprevalence during a time frame of 8 months
Measure: Proportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings / reasons, duration, frequency) and association with the level of seroprevalence Time: 8 monthsDescription: Strengths of associations between socio-behavioral factors and level of seroprevalence during a time frame of 8 months
Measure: Strengths of associations between socio-behavioral factors and level of seroprevalence Time: 8 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports